Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31429890 | 0.85 | MAPT (0.45) | NMT1ALOX15TSHRCA1CA2 | |
| SCHEMBL14930239 | 0.82 | NMT1 (0.54) | NMT1AKR1B1PFKFB4CYP3A4CYP2C9 | |
| SCHEMBL2371744 | 0.81 | NMT1 (0.52) | NMT1AKR1B1PFKFB4CYP3A4CYP2C9 | |
| SCHEMBL2371266 | 0.81 | CCR2 (0.53) | AKR1B1LMNAALDH1A1CCR2KAT6A | |
| SCHEMBL3020785 | 0.81 | NMT1 (0.52) | NMT1AKR1B1PFKFB4CYP3A4CYP2C9 | |
| SCHEMBL17342883 | 0.79 | GAA (0.48) | NMT1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL2372357 | 0.79 | CA1 (0.58) | NMT1CA1CA2MAPTLMNA | |
| SCHEMBL29430705 | 0.79 | NMT1 (0.49) | NMT1AKR1B1PFKFB4ALOX15TSHR | |
| SCHEMBL1581645 | 0.79 | NMT1 (0.49) | NMT1AKR1B1PFKFB4ALOX15TSHR | |
| SCHEMBL686390 | 0.78 | L3MBTL1 (0.43) | CA1CA2LMNAALDH1A1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | claimed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | claimed |
| WO-2026105054-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026105056-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | MET, MYC, HGFAC | NMT1 1540/4885AKR1B1 4335/4885PFKFB4 3197/4885 |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PIK3CD, PIK3CA, MTOR | NMT1 3550/4885AKR1B1 2870/4885PFKFB4 679/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | NMT1 1282/4885AKR1B1 1688/4885PFKFB4 1542/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | NMT1 1369/4885AKR1B1 69/4885PFKFB4 2191/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | NMT1 1369/4885AKR1B1 69/4885PFKFB4 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.